Therapeutic Radionuclides in Nuclear Medicine
Dear Colleagues, Recently, the theranostic principle has been used with tumor receptor-specific radiopharmaceuticals containing therapeutic nuclides, such as 161Tb, 177Lu, 188Re, 212Pb, and 225Ac. The production mode, availability, and costs of radionuclides have a significant impact on their clinic...
Na minha lista:
| Formato: | Online |
|---|---|
| Idioma: | inglês |
| Publicado em: |
MDPI - Multidisciplinary Digital Publishing Institute
2025
|
| Assuntos: | |
| Acesso em linha: | ONIX_20250220_9783725829385_498 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
| _version_ | 1869521469782884352 |
|---|---|
| collection | Directory of Open Access Books |
| description | Dear Colleagues, Recently, the theranostic principle has been used with tumor receptor-specific radiopharmaceuticals containing therapeutic nuclides, such as 161Tb, 177Lu, 188Re, 212Pb, and 225Ac. The production mode, availability, and costs of radionuclides have a significant impact on their clinical use and are often bottlenecks for broader applications. Therefore, cyclotron-produced neutrons could open a new era for producing relevant radionuclides. The identification of tumor-specific binding sites, the development of tumor-addressing conjugates, opportunities for enhanced target enrichment, and the protection of critical organs define the potential of therapeutic radiopharmaceuticals. The combination of radiotherapeutics with other pharmaceuticals to modulate the target or repair systems exploits synergistic effects. Combining radiotherapeutics with the body's immune system or immunotherapeutics raises hopes for immunization against cancer and could explain the success of targeted alpha therapy vs. targeted beta therapy. This reprint is dedicated to nuclear oncologists, health physicists, radiopharmacists, radiochemists, radiobiologists, and all other oncologists. We thank all our colleagues and would like to express our respect for their contributions to this reprint. |
| format | Online |
| id | doab-20.500.12854ir-153134 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2025 |
| publishDateRange | 2025 |
| publishDateSort | 2025 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1531342025-02-20T13:36:35Z Therapeutic Radionuclides in Nuclear Medicine Pretze, Marc Kotzerke, Jörg IGF2R osteosarcoma image-based dosimetry RAPID 89Zr 177Lu tissue cross-reactivity PET/CT 90Y PET dosimetry radionuclide therapy quantitative accuracy uncertainty analysis MRT scanner multicenter 203Pb 212Pb TOC cell uptake AR42 J molar activity (AM) neuroendocrine tumor (NET) somatostatin receptor (SST2) targeted alpha-therapy (TAT) targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics actinium-225 lanthanum-133 lead-212 lead-203 gold nanoparticles [198Au]AuNPs radioactive tumor therapy tumor angiogenesis RGD peptide 225Ac physical properties production routes theranostic application cisplatin radionuclides alpha-emitter cancer therapy combined treatment isobolograms adrenocortical carcinoma endoradiotherapy IMAZA alpha emitter high let theranostic selective internal radionuclide therapy (SIRT) 90Y glass microspheres hepatocellular carcinoma (HCC) transarterial chemoembolization (TACE) molecular radiotherapy peptide receptor radionuclide therapy neuroendocrine tumours thema EDItEUR::A The Arts::AT Performing arts::ATD Theatre studies thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology thema EDItEUR::A The Arts::AV Music Dear Colleagues, Recently, the theranostic principle has been used with tumor receptor-specific radiopharmaceuticals containing therapeutic nuclides, such as 161Tb, 177Lu, 188Re, 212Pb, and 225Ac. The production mode, availability, and costs of radionuclides have a significant impact on their clinical use and are often bottlenecks for broader applications. Therefore, cyclotron-produced neutrons could open a new era for producing relevant radionuclides. The identification of tumor-specific binding sites, the development of tumor-addressing conjugates, opportunities for enhanced target enrichment, and the protection of critical organs define the potential of therapeutic radiopharmaceuticals. The combination of radiotherapeutics with other pharmaceuticals to modulate the target or repair systems exploits synergistic effects. Combining radiotherapeutics with the body's immune system or immunotherapeutics raises hopes for immunization against cancer and could explain the success of targeted alpha therapy vs. targeted beta therapy. This reprint is dedicated to nuclear oncologists, health physicists, radiopharmacists, radiochemists, radiobiologists, and all other oncologists. We thank all our colleagues and would like to express our respect for their contributions to this reprint. 2025-02-20T13:36:33Z 2025-02-20T13:36:33Z 2025 book ONIX_20250220_9783725829385_498 9783725829385 9783725829378 https://directory.doabooks.org/handle/20.500.12854/153134 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/10416 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-2937-8 10.3390/books978-3-7258-2937-8 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725829385 9783725829378 192 Basel open access |
| spellingShingle | IGF2R osteosarcoma image-based dosimetry RAPID 89Zr 177Lu tissue cross-reactivity PET/CT 90Y PET dosimetry radionuclide therapy quantitative accuracy uncertainty analysis MRT scanner multicenter 203Pb 212Pb TOC cell uptake AR42 J molar activity (AM) neuroendocrine tumor (NET) somatostatin receptor (SST2) targeted alpha-therapy (TAT) targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics actinium-225 lanthanum-133 lead-212 lead-203 gold nanoparticles [198Au]AuNPs radioactive tumor therapy tumor angiogenesis RGD peptide 225Ac physical properties production routes theranostic application cisplatin radionuclides alpha-emitter cancer therapy combined treatment isobolograms adrenocortical carcinoma endoradiotherapy IMAZA alpha emitter high let theranostic selective internal radionuclide therapy (SIRT) 90Y glass microspheres hepatocellular carcinoma (HCC) transarterial chemoembolization (TACE) molecular radiotherapy peptide receptor radionuclide therapy neuroendocrine tumours thema EDItEUR::A The Arts::AT Performing arts::ATD Theatre studies thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology thema EDItEUR::A The Arts::AV Music Therapeutic Radionuclides in Nuclear Medicine |
| title | Therapeutic Radionuclides in Nuclear Medicine |
| title_full | Therapeutic Radionuclides in Nuclear Medicine |
| title_fullStr | Therapeutic Radionuclides in Nuclear Medicine |
| title_full_unstemmed | Therapeutic Radionuclides in Nuclear Medicine |
| title_short | Therapeutic Radionuclides in Nuclear Medicine |
| title_sort | therapeutic radionuclides in nuclear medicine |
| topic | IGF2R osteosarcoma image-based dosimetry RAPID 89Zr 177Lu tissue cross-reactivity PET/CT 90Y PET dosimetry radionuclide therapy quantitative accuracy uncertainty analysis MRT scanner multicenter 203Pb 212Pb TOC cell uptake AR42 J molar activity (AM) neuroendocrine tumor (NET) somatostatin receptor (SST2) targeted alpha-therapy (TAT) targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics actinium-225 lanthanum-133 lead-212 lead-203 gold nanoparticles [198Au]AuNPs radioactive tumor therapy tumor angiogenesis RGD peptide 225Ac physical properties production routes theranostic application cisplatin radionuclides alpha-emitter cancer therapy combined treatment isobolograms adrenocortical carcinoma endoradiotherapy IMAZA alpha emitter high let theranostic selective internal radionuclide therapy (SIRT) 90Y glass microspheres hepatocellular carcinoma (HCC) transarterial chemoembolization (TACE) molecular radiotherapy peptide receptor radionuclide therapy neuroendocrine tumours thema EDItEUR::A The Arts::AT Performing arts::ATD Theatre studies thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology thema EDItEUR::A The Arts::AV Music |
| topic_facet | IGF2R osteosarcoma image-based dosimetry RAPID 89Zr 177Lu tissue cross-reactivity PET/CT 90Y PET dosimetry radionuclide therapy quantitative accuracy uncertainty analysis MRT scanner multicenter 203Pb 212Pb TOC cell uptake AR42 J molar activity (AM) neuroendocrine tumor (NET) somatostatin receptor (SST2) targeted alpha-therapy (TAT) targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics actinium-225 lanthanum-133 lead-212 lead-203 gold nanoparticles [198Au]AuNPs radioactive tumor therapy tumor angiogenesis RGD peptide 225Ac physical properties production routes theranostic application cisplatin radionuclides alpha-emitter cancer therapy combined treatment isobolograms adrenocortical carcinoma endoradiotherapy IMAZA alpha emitter high let theranostic selective internal radionuclide therapy (SIRT) 90Y glass microspheres hepatocellular carcinoma (HCC) transarterial chemoembolization (TACE) molecular radiotherapy peptide receptor radionuclide therapy neuroendocrine tumours thema EDItEUR::A The Arts::AT Performing arts::ATD Theatre studies thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology thema EDItEUR::A The Arts::AV Music |
| url | ONIX_20250220_9783725829385_498 |